Global Blood Therapeutics Inc. plans to sell $100 million of common stock in a registered underwritten public offering.
The company granted the underwriter an option to buy up to $15 million of its common stock.
Global Blood plans to use the net proceeds to fund the clinical development of voxelotor for treating sickle cell disease, and other clinical trials. It also intends to use the net proceeds for other research and development activities, working capital and general corporate purposes.
Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.